About Syncytin-2
Syncytin-2 (ERVFRD-1) is a protein
from Homo sapiens identified by UniProt accession
P60508, 538 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Syncytin-2 |
| UniProt accession | P60508 |
| Gene | ERVFRD-1 |
| Organism | Homo sapiens |
| Length | 538 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- Facial wrinkling · score 0.09
- prostate carcinoma · score 0.09
- dental caries · score 0.06
- phosphatidylcholine measurement · score 0.05
- actinic keratosis · score 0.04
- neoplasm · score 0.04
- acute myeloid leukemia · score 0.04
- silver-Russell syndrome due to 11p15 microduplication · score 0.03
- cholesteryl ester measurement · score 0.03
- blood metabolite measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P60508-F1 | alphafold | PREDICTED | 60.84 | — |
Amino-acid sequence (538 residues)
MGLLLLVLIL TPSLAAYRHP DFPLLEKAQQ LLQSTGSPYS TNCWLCTSSS TETPGTAYPA SPREWTSIEA ELHISYRWDP NLKGLMRPAN SLLSTVKQDF PDIRQKPPIF GPIFTNINLM GIAPICVMAK RKNGTNVGTL PSTVCNVTFT VDSNQQTYQT YTHNQFRHQP RFPKPPNITF PQGTLLDKSS RFCQGRPSSC STRNFWFRPA DYNQCLQISN LSSTAEWVLL DQTRNSLFWE NKTKGANQSQ TPCVQVLAGM TIATSYLGIS AVSEFFGTSL TPLFHFHIST CLKTQGAFYI CGQSIHQCLP SNWTGTCTIG YVTPDIFIAP GNLSLPIPIY GNSPLPRVRR AIHFIPLLAG LGILAGTGTG IAGITKASLT YSQLSKEIAN NIDTMAKALT TMQEQIDSLA AVVLQNRRGL DMLTAAQGGI CLALDEKCCF WVNQSGKVQD NIRQLLNQAS SLRERATQGW LNWEGTWKWF SWVLPLTGPL VSLLLLLLFG PCLLNLITQF VSSRLQAIKL QTNLSAGRHP RNIQESPF
Explore Syncytin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets